Private Wealth Partners LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Private Wealth Partners LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,155 shares of the company’s stock after buying an additional 2,728 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of Private Wealth Partners LLC’s holdings, making the stock its 28th biggest position. Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $12,026,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. TBH Global Asset Management LLC grew its stake in shares of Johnson & Johnson by 0.8% during the 4th quarter. TBH Global Asset Management LLC now owns 18,921 shares of the company’s stock valued at $2,729,000 after purchasing an additional 142 shares during the period. Private Advisor Group LLC grew its stake in shares of Johnson & Johnson by 69.1% during the 4th quarter. Private Advisor Group LLC now owns 435,449 shares of the company’s stock valued at $62,975,000 after purchasing an additional 177,879 shares during the period. Keene & Associates Inc. grew its stake in shares of Johnson & Johnson by 5.9% during the 4th quarter. Keene & Associates Inc. now owns 20,328 shares of the company’s stock valued at $2,940,000 after purchasing an additional 1,134 shares during the period. Financial Perspectives Inc grew its stake in shares of Johnson & Johnson by 3.9% during the 4th quarter. Financial Perspectives Inc now owns 8,106 shares of the company’s stock valued at $1,172,000 after purchasing an additional 305 shares during the period. Finally, Alberta Investment Management Corp grew its stake in shares of Johnson & Johnson by 770.6% during the 4th quarter. Alberta Investment Management Corp now owns 127,976 shares of the company’s stock valued at $18,508,000 after purchasing an additional 113,276 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $162.35 on Friday. The stock’s fifty day moving average is $148.93 and its 200 day moving average is $155.88. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm has a market capitalization of $390.87 billion, a PE ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analysts Set New Price Targets

A number of research firms have issued reports on JNJ. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Bank of America cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.